The CEO of Novo Nordisk stepped in a strong weight loss competition with ELI Lilly

Nouvo Nord’s CEO Lars Fergard Yorgensen He stepped down as a competition in the drug space to lose weight that pressured the company’s shares.

“Given the challenges of the recent market, the decrease in the stock prices, and the desire of the Novo Nordisk Foundation, the Novo Nordisk Council and Lars Fergard Yorgensen jointly concluded that the start of the CEO of the CEO is in the interest of the company and its shareholders,” the company announced on Friday.

The company praised Jorgensen for his leadership, where it won it over the sales of Novo Nordisk and its profits and the price of the three -year stocks during his eight -year work as an executive president. However, the company’s shares have been successful since 2024.

Doctors draw attention to the safety issues related to the high weight loss drugs

The shares decreased by more than 50 % during the past year, eliminating more than $ 300 billion of their market value. The drug giant was racing against his competitors such as Eli Lily to control Weight loss space is very profitable.

Morgan Stanley Research expects that the global drug market for obesity will reach between 105 billion dollars and 144 billion dollars in 2030. This increases from a previous expectation of $ 77 billion. In 2023, sales of obesity with brands with $ 6 billion alone.

Sima Sistani CEO of Weightwatches in sudden exit, embraced weight loss medications

Wegovy from Novo Nordisk, which was approved by the FDA to manage chronic weight management in 2021, is the first time that one drug has been available and that helped patients get rid of total body weight, according to BMO CAPITAL Markets.

Although it was a landmark, Lily was quickly inflicted on its release, Zepbound, which was approved in 2023 and shows greater results for weight loss.

Novo Nordisk also manufactures OzemPIC, which is approved by FDA for Treating type 2 diabetes In the competition with Mounjaro Lilly, which was approved in 2022 to treat type 2 diabetes.

index	protection	last	Changing	% Change
Non -governmental organizations	Novo Nordisk A/S.	63.65	-2.51	-3.79 %
To	Eli Lily and Partners.	733.29	+17.73	+2.48 %

Yorgensen will remain in office as he continues to search for his successor. The company said that the CEO will remain “to support a smooth transition to a new leadership” when he is chosen behind. Searching for a continuous alternative.

Get Fox Business on the Go by clicking here

During his term, the company has grown dramatically, and its leadership in the care of diabetics, which created itself as a pioneer in the treatment of obesity and varied in other areas of serious chronic diseases.

Lars Ripan Sorensen, President of the Novo Nordisk Foundation, will join the Novo Nordsk Council.